Literature DB >> 3658827

Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept.

N Kyprianou1, J T Isaacs.   

Abstract

The shape of the prostatic dihydrotestosterone (DHT) dose vs prostatic cell number response curve can be used to determine if the androgen-induced increase in prostatic cell number occurs as a continuous graded process increasing with all levels of prostatic DHT, or whether the process is quantal, beginning to occur only when a critical threshold of prostatic DHT is reached. To make this determination, castrated-adrenalectomized rats, castrated rats given no treatment, and castrated rats given testosterone-filled silastic implants of varying lengths were used to construct such a prostatic DHT dose/prostatic cell number response curve ranging from undetectable to pharmacologically high levels of prostatic DHT. The shape of this dose-response curve was found not to be continuously hyperbolic, but instead, to be discontinuously sigmoidal. This demonstrates that, in the rat, androgen-induced increase in prostatic cell number occurs as a quantal process which can only begin when the concentration of prostatic DHT is above a critical threshold value (ie, 0.4 ng/10(8) cells for the rat ventral prostate). Thus, in order to completely prevent this androgenic stimulation of prostatic cell number, the prostatic DHT level has to be lowered to below this critical threshold but does not have to be completely eliminated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3658827     DOI: 10.1002/pros.2990110106

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

Review 1.  Morphologic and regulatory aspects of prostatic function.

Authors:  G Aumüller
Journal:  Anat Embryol (Berl)       Date:  1989

2.  Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells.

Authors:  Yulius Y Setiady; Katsuhiro Ohno; Eileen T Samy; Harini Bagavant; Hui Qiao; Colin Sharp; Jin Xiong She; Kenneth S K Tung
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

3.  Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Yi Xu; Lizamma Antony; Susan L Dalrymple; John T Isaacs
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

Review 4.  Review of assessment of total androgen blockade as treatment of metastatic prostate cancer.

Authors:  J Geller
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

5.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

6.  Post-castration rebound of an androgen regulated prostatic gene.

Authors:  R Sweetland; P C Sheppard; J G Dodd; R J Matusik
Journal:  Mol Cell Biochem       Date:  1988-11       Impact factor: 3.396

7.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

8.  Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.

Authors:  W M van Weerden; A van Kreuningen; E P Moerings; F H de Jong; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1991

9.  Growth-stimulating effect of adrenal androgens on the R3327 Dunning prostatic carcinoma.

Authors:  C D Schiller; M R Schneider; H Hartmann; A H Graf; H Klocker; G Bartsch
Journal:  Urol Res       Date:  1991

10.  Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Authors:  Mohammad Hedayati; Michael C Haffner; Jonathan B Coulter; Raju R Raval; Yonggang Zhang; Haoming Zhou; Omar Mian; Emma J Knight; Nina Razavi; Susan Dalrymple; John T Isaacs; Aileen Santos; Russell Hales; William G Nelson; Srinivasan Yegnasubramanian; Theodore L DeWeese
Journal:  Clin Cancer Res       Date:  2016-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.